Nathan L. Mata
Directeur Technique/Scientifique/R&D chez BELITE BIO, INC
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Yue Hsin Lin | M | 46 |
Belite Bio LLC
 Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | 6 ans |
| Gary Clark Biddle | M | 72 | 2 ans | |
| Yi Ta Lue | M | 47 | 2 ans | |
| John Longo | M | 55 | 2 ans | |
| Jennifer Wu | F | - | - | |
| Cheng Chi Wang | M | - |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | 8 ans |
| Hao Yuan Chuang | M | 40 | 4 ans | |
| Hung Wei Chen | F | 43 | 3 ans | |
| Ching Chen Chiu | F | 55 | 3 ans | |
| Wan Shan Chen | F | 38 | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jay Lichter | M | 62 |
ReVision Therapeutics, Inc.
 ReVision Therapeutics, Inc. Drugstore ChainsRetail Trade ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. The firm operates as a ophthalmic biopharmaceutical company. Its products include Fenretinide, an oral medication that reduces the accumulation of A2E in the retina, and slows down the growth of atrophic lesions, which precedes vision loss. The company was founded in April 2010 and is headquartered in La Jolla, CA.
Sytera, Inc.
 Sytera, Inc. BiotechnologyHealth Technology Part of Bausch Health Cos., Inc., Sytera, Inc. is a biopharmaceutical company that provides biopharmaceutical services and products. The company is based in La Jolla, CA. The company was founded by Jay B. Lichter, Kenneth J. Widder, Nathan L. Mata. Sytera was acquired by Sirion Therapeutics, Inc. on August 16, 2006 for $250 million. | 1 ans |
| Todd Creech | M | 56 |
Sirion Therapeutics, Inc.
 Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | 4 ans |
| Thomas M. Riedhammer | M | 76 |
Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | 6 ans |
| Curt LaBelle | M | 53 |
Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | 2 ans |
| C. Christine Miller | M | - |
Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | 4 ans |
| Drey Coleman | F | - |
Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | 4 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 16 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Nathan L. Mata
- Réseau Personnel
